Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A participant was to meet all of the following criteria to be eligible for this study:~* The participant and/or the participant's parent/legal guardian was willing and able to provide signed informed consent.~* The participant had a confirmed acid alpha-glucosidase (GAA) enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.~* Infant and toddler Pompe disease participants could be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) would not exceed 3 percent (%) of the total blood volume during a period of 4 weeks and would not exceed 1 % at any single time.~* The participant, if female and of childbearing potential, must have had a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female participants of childbearing potential and sexually mature males must have agreed to use a medically accepted method of contraception throughout the study.~* For participants previously treated with alglucosidase alfa the participant had received alglucosidase alfa for at least 6 months.~Exclusion Criteria:~A participant who met any of the following criteria was excluded from this study:~* The participant was participating in another clinical study using an investigational product.~* The participant, in the opinion of the Investigator, was unable to adhere to the requirements of the study.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alglucosidase alfa (Type: EXPERIMENTAL): Participants received intravenous (IV) infusion of Alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight on Day 1. Infusion was administered at an initial rate of approximately 1 milligram per kilogram per hour (mg/kg/hr) with allowed rate increased of 2 mg/kg/hr every 30 minutes, if there were no signs of infusion-associated reactions (IARs), until a maximum rate of approximately 7 mg/kg/hr was reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).